Abstract:A better mechanistic understanding of virus-host dependencies can help reveal vulnerabilities and identify opportunities for therapeutic intervention. Of particular interest are essential interactions that enable production of viral proteins, as those could target an early step in the virus lifecycle. Here, we use subcellular proteomics, ribosome profiling analyses and reporter assays to detect changes in protein synthesis dynamics during SARS-CoV-2 (CoV2) infection. We identify specific translation factors and molecular chaperones that are used by CoV2 to promote the synthesis and maturation of its own proteins. These can be targeted to inhibit infection, without major toxicity to the host. We also find that CoV2 non-structural protein 1 (Nsp1) cooperates with initiation factors EIF1 and 1A to selectively enhance translation of viral RNA. When EIF1/1A are depleted, more ribosomes initiate translation from a conserved upstream CUG start codon found in all genomic and subgenomic viral RNAs. This results in higher translation of an upstream open reading frame (uORF1) and lower translation of the main ORF, altering the stoichiometry of viral proteins and attenuating infection. Replacing the upstream CUG with AUG strongly inhibits translation of the main ORF independently of Nsp1, EIF1, or EIF1A. Taken together, our work describes multiple dependencies of CoV2 on host biosynthetic networks and proposes a model for dosage control of viral proteins through Nsp1-mediated control of translation start site selection. Host-directed antivirals offer a promising therapeutic approach for many viruses, including SARS-CoV-2 (CoV2), but their development requires a deeper understanding of virus-host interactions. Of particular interest are interactions that selectively promote the synthesis of viral proteins, including RNA-binding proteins, translation factors and molecular chaperones. Drugs that inhibit such biosynthetic factors have already entered clinical trials for multiple indications. To identify new cellular targets for intervention, we isolated translating ribosomes from CoV2-infected and control cells and analyzed their interacting partners by mass-spectrometry. We found multiple biosynthetic factors that were specifically enriched on polysomes translating CoV2, including translation initiation factors EIF1 and 1A. These factors control translation start site selection, cooperate with the viral non-structural protein 1 (Nsp1) to selectively enhance translation of viral genomic RNA, and are exploited by CoV2 to regulate the timing and stoichiometry of viral protein synthesis. Targeting EIF1A by siRNA reduces infection with minimal toxicity to the host. Although the nature of interactions between EIF1/1A and Nsp1 remains unclear, this interdependency may provide a new strategy for antiviral therapy.

SARS-CoV-2 couples evasion of inflammatory response to activated nucleotide synthesis

SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response

Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2

Targeting liquid–liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity

Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA

Exploring nucleoside analogs: key targets in the viral life cycle - advancing strategies against SARS-CoV-2

Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19

Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective

SARS-CoV-2 Nsp1 cooperates with initiation factors EIF1 and 1A to selectively enhance translation of viral RNA

COVID-19 Molecular Pathophysiology: Acetylation of Repurposing Drugs

Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options

SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication

Targeting TRIM28-mediated SUMOylation of SARS-CoV-2 Nucleocapsid Protein Inhibits SARS-CoV-2 Infection

Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion

The Impact of SARS-CoV-2 nsp14 Proofreading on Nucleoside Antiviral Activity: Insights from Genetic and Pharmacological Investigations

Nucleotide analogues as inhibitors of SARS-CoV Polymerase

Chain Termination Effects of Chemically Modified Nucleoside Analogs on SARS-CoV-2 RNA Polymerase

Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera

Repurposing Niclosamide as a Novel Anti-SARS-CoV-2 Drug by Restricting Entry Protein CD147

Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function

The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme